TRIUMEQ PD Drug Patent Profile

When do Triumeq Pd patents expire, and when can generic versions of Triumeq Pd launch?

Triumeq Pd is a drug marketed by Viiv Hlthcare and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fifty-seven patent family members in thirty-five countries.

The generic ingredient in TRIUMEQ PD is abacavir sulfate; dolutegravir sodium; lamivudine. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the abacavir sulfate; dolutegravir sodium; lamivudine profile page.

DrugPatentWatch^® Generic Entry Outlook for Triumeq Pd

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 8, 2030. This may change due to patent challenges or generic licensing.

There have been twenty-four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRIUMEQ PD

International Patents:	157
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	20
Drug Prices:	Drug price information for TRIUMEQ PD
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRIUMEQ PD
DailyMed Link:	TRIUMEQ PD at DailyMed

See drug prices for TRIUMEQ PD

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRIUMEQ PD

NDA:

215413

Dosage:

TABLET, FOR SUSPENSION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRIUMEQ PD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Macquarie University, Australia	PHASE3
Macquarie University, Australia	Phase 3
Stichting TRICALS Foundation	Phase 3

See all TRIUMEQ PD clinical trials

Paragraph IV (Patent) Challenges for TRIUMEQ PD

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRIUMEQ PD	Tablets for Oral Suspension	abacavir sulfate; dolutegravir sodium; lamivudine	60 mg/5 mg/30 mg	215413	1	2023-03-31

US Patents and Regulatory Information for TRIUMEQ PD

TRIUMEQ PD is protected by two US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes					Y
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes					Y

International Patents for TRIUMEQ PD

When does loss-of-exclusivity occur for TRIUMEQ PD?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hong Kong

Japan

Mexico

Russian Federation

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRIUMEQ PD around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	2008005137	DERIVADO DE CARBAMOILPIRIDONA POLICICLICA QUE TIENE ACTIVIDAD INHIBIDORA EN VIH INTEGRASA. (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE.)
European Patent Office	2527007	Dérivé de carbamoylpyridone polycyclique doté d'une activité inhibitrice de l'intégrase du VIH (Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity)
Eurasian Patent Organization	014162	ПОЛИЦИКЛИЧЕСКОЕ КАРБАМОИЛПИРИДОНОВОЕ ПРОИЗВОДНОЕ, ОБЛАДАЮЩЕЕ ИНГИБИТОРНОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ИНТЕГРАЗЫ ВИЧ (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY)

Supplementary Protection Certificates for TRIUMEQ PD

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1874117	2023C/545	Belgium		PRODUCT NAME: DOULUTEGRAVIR SODIQUE; AUTHORISATION NUMBER AND DATE: EU/1/13/892 20140121
2465580	PA2021512	Lithuania		PRODUCT NAME: KABOTEGRAVIRAS; REGISTRATION NO/DATE: EU/1/20/1481 20201217
2465580	C20210013 00397	Estonia		PRODUCT NAME: KABOTEGRAVIIR;REG NO/DATE: EU/1/120/1481; 21.12.2020

Triumeq PD: Patent Landscape and Market Projections

Last updated: February 19, 2026

Triumeq PD, a fixed-dose combination antiviral treatment for HIV-1 infection, faces a complex patent landscape and a dynamic market. Multiple patent families are active, with expirations ranging from 2025 to 2034, influencing market exclusivity and generic competition timelines. The drug's current market performance is robust, driven by its efficacy, convenience, and established safety profile, but future growth will be shaped by evolving treatment guidelines, the emergence of new therapies, and the impact of biosimilar competition.

What is Triumeq PD and What is its Target Indication?

Triumeq PD is a single-tablet regimen (STR) comprising dolutegravir (DTG), abacavir (ABC), and lamivudine (3TC). It is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents. The drug targets viral replication by inhibiting the integrase, reverse transcriptase, and polymerase enzymes essential for the HIV lifecycle.

What are the Key Patents Covering Triumeq PD and When Do They Expire?

The patent protection for Triumeq PD is multifaceted, involving patents for the individual active pharmaceutical ingredients (APIs) as well as the fixed-dose combination itself.

• Dolutegravir (DTG) Patents:

  • US Patent No. 8,124,627: Covers methods of preparing dolutegravir. Original expiration date: October 14, 2025. This patent has faced legal challenges.
  • US Patent No. 8,822,439: Covers crystalline forms of dolutegravir sodium. Original expiration date: February 11, 2029.
  • US Patent No. 9,481,775: Covers processes for preparing dolutegravir. Original expiration date: February 11, 2029.
  • Further patents covering dolutegravir and its formulations exist globally, with varying expiration dates in different jurisdictions.

• Abacavir (ABC) and Lamivudine (3TC) Patents:

  • Abacavir and lamivudine are older antiretrovirals, and their primary composition of matter patents have expired. However, secondary patents related to specific formulations, manufacturing processes, or polymorphs may still be active. For example, patents related to abacavir sulfate formulations or specific manufacturing routes could extend market exclusivity for certain aspects of its production. Specific patent numbers and expiration dates for these secondary patents are numerous and require detailed analysis by jurisdiction.

• Fixed-Dose Combination (FDC) Patents:

  • US Patent No. 9,545,404: Covers the fixed-dose combination tablet comprising DTG, ABC, and 3TC. Original expiration date: November 19, 2034. This patent is crucial for protecting the specific co-formulation of Triumeq PD.
  • Other patents related to the co-formulation, manufacturing processes for the FDC, and specific dosage forms are also in effect.

• Exclusivity Periods:

  • Orphan Drug Exclusivity: Not applicable for Triumeq PD as HIV is not designated as a rare disease for orphan drug purposes in major markets like the US and EU.
  • New Chemical Entity (NCE) Exclusivity: Dolutegravir received NCE exclusivity. In the US, this is typically 5 years from approval for drugs that do not meet other exclusivity criteria. Triumeq PD is a combination product, and the exclusivity for the individual components and the combination itself is what dictates market protection.
  • Pediatric Exclusivity: In the US, pediatric exclusivity can extend patent protection by 6 months. The application for pediatric studies for dolutegravir and related combinations has been considered by the FDA. Specific extension details depend on the timing and successful completion of approved pediatric trials.

Summary of Key Patent Expirations (US Focus):

Patent Type	Key Patent Number(s)	Primary Active Ingredient(s)	Original Expiration (US)
API (DTG)	8,124,627	Dolutegravir	October 14, 2025
API (DTG)	8,822,439	Dolutegravir	February 11, 2029
API (DTG)	9,481,775	Dolutegravir	February 11, 2029
Fixed-Dose Combination	9,545,404	DTG, ABC, 3TC	November 19, 2034

Note: Expiration dates can be subject to adjustments due to patent term extensions (PTE) or adjustments (PTA) granted to compensate for regulatory review delays. Legal challenges can also alter effective patent protection.

What is the Current Market Size and Growth Trajectory for Triumeq PD?

Triumeq PD (marketed as Triumeq in the US and other regions) has achieved significant market penetration and revenue generation.

• 2023 Global Sales: Approximately $7.5 billion USD [1]. This represents a slight decrease from 2022 sales of $7.9 billion USD, indicating market maturation and increasing competition.
• Market Share: Triumeq PD has been a leading single-tablet regimen for initial HIV treatment. Its market share within the dolutegravir-containing STR segment has been substantial.
• Growth Drivers:
  • Established Efficacy and Safety: Long-term data supports its effectiveness and tolerability profile.
  • Convenience: Single-tablet regimen simplifies adherence for patients.
  • Physician and Patient Preference: It is a preferred option in many treatment guidelines.
  • Global Reach: Broad market access across developed and emerging economies.
• Growth Hindrances:
  • Market Saturation: The market for initial HIV therapy is highly competitive.
  • Generic Competition: Approaching patent expirations for key components and the combination product will lead to generic entry.
  • Emergence of New Therapies: Development of novel ARV agents, including long-acting injectables and alternative STRs, poses a competitive threat.
  • Pricing Pressures: Increasing scrutiny on drug pricing globally.

Projected Market Trajectory:

The market for Triumeq PD is expected to experience a decline in the coming years due to the aforementioned factors. While specific revenue projections vary by analyst, consensus indicates a contraction of annual sales as generic versions of dolutegravir, and subsequently the Triumeq PD combination, become available. The impact will be most significant in markets where generic approvals occur earliest.

How Do Treatment Guidelines Influence Triumeq PD's Market Position?

HIV treatment guidelines are a critical determinant of drug utilization and market dynamics. Triumeq PD's position has been historically strong, but evolving recommendations may shift its standing.

• US Department of Health and Human Services (DHHS) Guidelines:

  • Historically, dolutegravir-based regimens, including those in Triumeq PD, have been recommended as preferred options for initial HIV treatment for most individuals. This recommendation is based on high barrier to resistance, favorable efficacy, and a good safety profile.
  • The guidelines emphasize integrase strand transfer inhibitors (INSTIs) as a preferred drug class.
  • Guideline updates consider new drug approvals, emerging resistance patterns, and long-term safety data. Recent updates have continued to support dolutegravir-containing regimens, but newer INSTIs and alternative STRs are also being evaluated and incorporated.

• European AIDS Clinical Society (EACS) Guidelines:

  • Similar to US guidelines, EACS recommends INSTI-based regimens as first-line therapy. Dolutegravir is often listed as a preferred option.
  • The guidelines are dynamic and are updated to reflect new clinical trial data and drug approvals.

• Impact of Guidelines on Triumeq PD:

  • Positive Impact: Inclusion as a preferred regimen has driven significant uptake and maintained market leadership.
  • Potential Negative Impact: Future guideline revisions could de-emphasize Triumeq PD if newer, equally or more effective, or safer alternatives emerge with improved long-term outcomes or better resistance profiles. The introduction of new fixed-dose combinations or long-acting injectables that are recommended in guidelines could also reduce Triumeq PD's market share.

What are the Key Competitive Threats to Triumeq PD?

Triumeq PD faces a multi-pronged competitive landscape from both branded and generic competitors.

• Other Dolutegravir-Containing Regimens:

  • Juluca: (dolutegravir/rilpivirine) - a two-drug STR for maintenance therapy, not initial treatment.
  • Dovato: (dolutegravir/lamivudine) - a two-drug STR for initial treatment. This is a significant competitor, offering a simpler regimen with fewer components.
  • Cabenuva: (cabotegravir/rilpivirine) - a long-acting injectable regimen. While not an STR, it offers an alternative treatment modality that addresses adherence concerns and may appeal to a segment of patients.

• Regimens Utilizing Other INSTIs:

  • Biktarvy: (bictegravir/emtricitabine/tenofovir alafenamide) - a widely prescribed INSTI-based STR that has gained significant market share. Its efficacy, favorable tolerability profile, and high barrier to resistance make it a primary competitor.
  • Genvoya: (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) - another INSTI-based STR.

• Generic Competition:

  • Dolutegravir Generics: As the patent for dolutegravir (US 8,124,627) approaches expiration, generic versions of dolutegravir will become available. This will likely lead to price erosion for dolutegravir-containing products.
  • Abacavir and Lamivudine Generics: Generic abacavir and lamivudine have been available for years, but their inclusion in an STR with dolutegravir provided the branded product with protection.
  • Generic Triumeq PD: Following the expiration of patents covering the fixed-dose combination itself (e.g., US 9,545,404), generic versions of Triumeq PD will be able to enter the market. This is expected to significantly impact sales due to price competition. The timing of these generic entries is critical.

• Emerging Therapies:

  • Long-Acting Injectables: The development of longer-acting injectable antiretroviral therapies represents a paradigm shift in HIV treatment, offering an alternative to daily oral pills.
  • Novel Antiretroviral Classes: Research continues into new mechanisms of action that could offer improved efficacy, tolerability, or resistance profiles.

What is the Financial Trajectory and Outlook for Triumeq PD?

The financial trajectory of Triumeq PD is characterized by its current success as a blockbuster drug, followed by an anticipated decline due to patent expirations and increased generic competition.

• Revenue Peaks and Declines:

  • Triumeq PD reached peak annual sales in the fiscal year 2022.
  • Sales have begun to decline, a common pattern for highly successful drugs approaching patent cliffs.
  • Further significant revenue erosion is projected from 2025 onwards, accelerating with the entry of generic competitors to the fixed-dose combination.

• Impact of Patent Expirations:

  • The expiration of key dolutegravir patents (e.g., US 8,124,627 in 2025) will enable generic dolutegravir. This could lead to market entry of generic dolutegravir-only products or other dolutegravir-containing STRs.
  • The expiration of the FDC patent (US 9,545,404 in 2034) is the ultimate determinant for generic Triumeq PD. However, prior generic entry of its components or competing INSTI STRs will influence its market position leading up to that date.

• R&D Investment and Lifecycle Management:

  • For the innovator company (ViiV Healthcare, a GSK/Pfizer/Shionogi joint venture), the focus will shift from maximizing Triumeq PD's current revenue to managing its decline and developing next-generation therapies or alternative formulations.
  • Investments may be directed towards lifecycle management strategies, such as exploring new indications (though unlikely for an established HIV therapy) or developing improved delivery systems, though these are often limited by patent constraints.

• Market Valuation and Investment Considerations:

  • For investors, the diminishing patent exclusivity of Triumeq PD signals a reduction in future revenue streams for the innovator.
  • The market for HIV treatment remains substantial, but growth is increasingly driven by newer therapies and generics.
  • Investment decisions should consider the timing of generic entry, the competitive strength of alternative treatments, and the overall pipeline of the company marketing Triumeq PD.

Financial Outlook Summary:

Triumeq PD is in the mature phase of its product lifecycle. While it continues to generate substantial revenue, its market exclusivity is progressively eroding. The primary financial challenge is the impending wave of generic competition, which will significantly reduce its market share and revenue. Projections indicate a steady decline in sales over the next decade.

Key Takeaways

• Triumeq PD faces patent expirations for its active pharmaceutical ingredients and the fixed-dose combination, with key patents expiring between 2025 and 2034.
• The drug has achieved substantial market success, generating billions in annual revenue, driven by its efficacy and convenience as a single-tablet regimen.
• Competitive threats include other dolutegravir-based regimens (e.g., Dovato), alternative INSTI-based STRs (e.g., Biktarvy), and emerging long-acting injectable therapies.
• Generic competition for dolutegravir and the Triumeq PD combination is the primary factor expected to drive significant revenue decline from 2025 onwards.
• HIV treatment guidelines continue to support INSTI-based regimens, but evolving recommendations and new drug approvals will influence Triumeq PD's future market position.
• The financial outlook for Triumeq PD is characterized by a mature product lifecycle and an anticipated decline in sales due to patent cliffs.

Frequently Asked Questions

1. When does the primary patent for dolutegravir expire in the United States? The original expiration date for US Patent No. 8,124,627, covering methods of preparing dolutegravir, is October 14, 2025.

2. What is the significance of the patent expiring in 2034 for Triumeq PD? US Patent No. 9,545,404, which covers the fixed-dose combination tablet of dolutegravir, abacavir, and lamivudine, is set to expire in November 2034. This patent's expiration is critical as it protects the specific formulation of Triumeq PD, enabling generic versions of the combination product to enter the market.

3. Which alternative single-tablet regimens (STRs) pose the most significant competition to Triumeq PD? Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a major competitor due to its efficacy and favorable tolerability. Dovato (dolutegravir/lamivudine), a two-drug STR, also presents a competitive challenge by offering a simplified regimen.

4. Are there any long-acting injectable treatments that compete with Triumeq PD? Yes, Cabenuva (cabotegravir/rilpivirine) is a long-acting injectable regimen that offers an alternative treatment modality for HIV, competing for patients who may prefer or benefit from non-daily oral dosing.

5. What is the projected impact of generic competition on Triumeq PD's revenue? Generic competition, particularly for dolutegravir and later for the Triumeq PD combination itself, is expected to lead to significant price erosion and a substantial decline in Triumeq PD's annual revenue, commencing around 2025 and accelerating thereafter.

Citations

[1] ViiV Healthcare. (2024). Full year results for the twelve months ended 31 December 2023. GSK plc. Retrieved from https://www.gsk.com/media/press-releases/2024/full-year-results-for-the-twelve-months-ended-31-december-2023/